Advertisement

Topics

Companies Related to "Platelet-Inhibitor Drug Trial in Coronary Angioplasty" [Most Relevant Company Matches] RSS

08:34 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Platelet-Inhibitor Drug Trial in Coronary Angioplasty" found in our extensive corporate database of over 50,000 company records.

Showing "Platelet Inhibitor Drug Trial Coronary Angioplasty" Companies 1–25 of 4,200+

Relevant

Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary interve...


PLC Systems

PLC is a global leader in the development of products for performing a revolutionary new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a completely new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease is the leading cause of death in the United States. Working with leading researchers and premier heart...

CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase III trial to treat der...


EndoCross, Ltd.

Privately held EndoCross Ltd., headquartered in Yokneam Israel, and with operations in Amherst, New Hampshire (USA), has developed a proprietary system for the crossing of Chronic Total Occlusion (CTO). Through a combination of a unique balloon catheter design and the incorporation of a novel automated inflation system, the company’s ENABLER Catheter ...

Accumetrics

Accumetrics develops, manufactures, and markets the VerifyNow™ System, a comprehensive system for the assessment of platelet function. Modulation of platelet function plays a critical role in effectively treating cardiovascular, cerebrovascular, and peripheral vascular disease. VerifyNow is the only rapid platelet function test shown to correlate with clinical outcomes. The tests provide doctors...

Platelet BioGenesis

Platelet BioGenesis is a venture-backed, development stage biotech company creating designer platelets (PLTs+™) as a new class of therapeutics. Platelet BioGenesis has developed and patented a scalable cGMP-compliant process to generate PLTs+™ from clinical grade induced pluripotent stem cells. The company was spun out of Harvard University and h...

Accumetrics Inc.

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

CorNova Inc.

CorNova is a developer of next-generation endovascular products designed to integrate new technologies into existing products and procedures, resulting in better patient outcomes without added procedure time, cost and patient risk. The company's FiberHalo(TM) stent deployment and post-dilatation angioplasty balloon catheters are designed to provide stent lumen area measurement within the angiopla...

Accumetrics, Inc.

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

The Medicines Company

The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon ang...

Medicines Co.

The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon ang...

REVA Medical, Inc.

REVA is dedicated to developing minimally invasive medical devices that leverage the Company's proprietary biomaterial and stent technologies to improve the treatment of disease. Guided by a management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA's initial focus is the development and eventual commercialization of...

NOVOSTE

Novoste Corporation, based in Atlanta, Georgia, develops advanced medical treatments for coronary and vascular diseases and is the worldwide leader in vascular brachytherapy - radiation therapy delivered inside a blood vessel to prevent its reclosure (restenosis) following balloon angioplasty and other catheter-based interventional procedures. The NovosteT Beta-CathT System is commercially availab...

Arterial Remodeling Technologies (“ART”)

Arterial Remodeling Technologies (“ART”) is developing bioresorbable coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre ...

Sunshine Heart, Inc.

Sunshine Heart (ASX:SHC) is a global medical device company committed to novel cardiac and coronary therapy. The company is currently developing the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-...

ACT Biotech Inc.

ACT Biotech (www.actbiotech.com) is a San Francisco-based, privately-held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs. The Company's clinical stage pipeline also includes Telatinib, the most selective oral VEGF/PDGFR/KIT inhibitor ever developed. Telatinib is currently being studied in a Phase 2 trial...

BioCytex

Since the foundation of Biocytex in the early 90's in the close proximity of the University and Hospital Complex of La Timone / La Conception in Marseille (France), the need of standardization in flow cytometry analysis still remains a topic of concern. Inter-laboratory reproducibility, day to day reproducibility and positivity and/or negativity threshold determination are a real need that can be ...

Invatec

Headquartered in Italy and with manufacturing in Italy and Switzerland, Invatec is one of the world’s fastest growing companies in the design, development and production of interventional cardiology and peripheral vascular products for the treatment of coronary and peripheral arterial disease. Driven by research and technology, Invatec actively collab...

Provisio, Inc

Headquartered in Nashville, TN, Provisio, Inc. develops technologies and services that enhance clinical trial processes. Its flagship solution, iTrials, automates and streamlines the way drug trial candidates are identified, notified and enrolled. iTrials breaks the traditional paradigm associated with lengthy and costly clinical trial enrollment. Leveraging iTrials "unique-to-industry" data wareh...

S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug ...

Verax Biomedical

Verax is the producer of the Platelet PGD Test, the only test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can now also be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for signif...

Auspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals is a privately held biopharmaceutical company located in La Jolla, California. The company is a pioneer in the use of deuterium in medicinal chemistry, and is focused on the treatment of hyperkinetic movement disorders including Huntington’s disease, Tourette syndrome and tardive dyskinesia. Its lead compound, SD-809, is a novel ...

PlaqueTec Ltd.

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory risk. It has been proven to detect inflammatory molecules across the site of coronary artery disease (CAD), and can discriminate between patients with greater and lesser levels of co...

Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel ...


More From BioPortfolio on "Platelet-Inhibitor Drug Trial in Coronary Angioplasty"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks